Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Marianna Fontana(Amyloidosis Foundation), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Ronald Witteles(Alnylam Pharmaceuticals (United States)), John L. Berk(Boston University), Kenichi Tsujita(Kumamoto University), José González‐Costello(British Heart Foundation), Steen Hvitfeldt Poulsen(Aarhus University Hospital), Diego Delgado(British Heart Foundation), Antoine Bondue, Elena Yureneva(British Heart Foundation), Zoltán Pozsonyi(British Heart Foundation), Farooq H. Sheikh(MedStar Washington Hospital Center), Scott D. Solomon(Brigham and Women's Hospital), Katherine L. Boyle(British Heart Foundation), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Ali Abbas Yılmaz(British Heart Foundation), Pablo García‐Pavía(Universidad Francisco de Vitoria), Vincent Algalarrondo(British Heart Foundation), Darae Kim(British Heart Foundation), Nancy Silliman(British Heart Foundation), Brian Drachman(British Heart Foundation), Thibaud Damy(Amyloidosis Foundation), Pushkal Garg(Université Paris-Sud), Martha Grogan(Mayo Clinic in Arizona), Ewa A. Jankowska(Wroclaw Medical University), Nobuhiro Tahara(British Heart Foundation), Jörg Täubel(British Heart Foundation), Caroline Morbach(British Heart Foundation), Andrew Slugg(British Heart Foundation), Jihong Chen(Université Paris-Sud), Peter van der Meer(University Medical Center Groningen), Satish A. Eraly(British Heart Foundation), Lilli Yang(British Heart Foundation), Olga Azevedo(British Heart Foundation), Andrew Jabbour(British Heart Foundation), Mark C. Petrie(British Heart Foundation)
Cited by 356
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k